Accelerate Diagnostics Welcomes Dr. Charles Watts to its Board of Directors
November 16 2017 - 12:06PM
Accelerate Diagnostics, Inc. today announced the election of
Charles Watts, M.D. to the company’s board of directors. His
appointment is effective November 14, 2017.
Dr. Watts has held a number of clinical and administrative
leadership positions at two renowned academic medical centers,
Northwestern (Feinberg School of Medicine, Northwestern Memorial
Hospital) and the University of Michigan, and with his training and
extensive clinical career as a Pulmonary-Critical Care specialist,
he adds a comprehensive background of clinical practice and
healthcare administration to the company’s Board of Directors.
Dr. Watts served as Chief Medical Officer at Northwestern
Memorial Hospital (NMH) and Associate Dean for Clinical Affairs at
the Feinberg School of Medicine, Northwestern University from 2001
to 2011. He directed the quality and patient safety programs and
was responsible for oversight and support of the clinical programs
at NMH, which was recognized as a national leader in quality of
care by the University Health System Consortium and Leapfrog, among
others. His teaching activities included courses at Kellogg
(Introduction to the American Healthcare System) and the Masters
Program in Patient Safety.
Prior to his tenure at Northwestern, Dr. Watts served as Chief
of Clinical Affairs and Associate Dean at the University of
Michigan Medical Center. While at Michigan he was Medical Director
of Critical Care and actively involved in a number of multi-center
critical care research projects including the Acute Respiratory
Distress Syndrome (ARDS) Network and the development and
implementation of the APACHE score, a nationally used tool for
measuring severity of illness and predicting outcomes in critically
ill patients. He received his undergraduate and medical degrees
from the University of Michigan. His research interests have
included severity adjustment in the ICU, quality improvement
measurement, and acute respiratory distress syndrome. He has also
served as Executive in Residence for the Health Management Academy,
as an active faculty member of a nationally based Physician
Leadership Program.
Dr. Watts has served as a Director of Providence Health and
Services (Seattle, Washington) from 2012 to 2016 where he chaired
the Quality and Patient Safety Improvement Committee, and recently
served as a Trustee of Swedish Health Services, Inc. until June of
this year. He currently serves as a Trustee on the Institute for
Systems Biology Board (Seattle, Washington).
“Chuck brings a career of valuable experiences to our board that
complements our current team. His experience as a CMO of leading
health care providers will enhance our ability to continue building
consensus around the essential value of our innovative technology,”
said Chairman, John Patience. “In addition to bolstering a
significant impact with key decision makers in the C-Suite, his
broad clinical experience will be invaluable to our strategic
marketing and R&D teams in mapping out future products."
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. (Nasdaq:AXDX), is an in vitro
diagnostics company dedicated to providing solutions for the global
challenge of antibiotic resistance and healthcare-associated
infections. The company recently obtained FDA marketing
authorization for antimicrobial susceptibility testing direct from
positive blood culture samples using its Accelerate Pheno™ system
and Accelerate PhenoTest™ BC kit. The system and kit leverage
proprietary molecular identification methods and morphokinetic
cellular analysis (MCA) to provide minimum inhibitory
concentrations for a range of applicable antibiotics. The
fully-automated system is designed to eliminate the lengthy culture
and sample preparation steps required prior to antimicrobial
susceptibility testing. Recent market studies suggest the solution
offers results 1-2 days faster than conventional methods, enabling
clinicians to optimize antibiotic selection, dosage, and infusion
strategy specific to the individual patient and their
infection.
The “ACCELERATE DIAGNOSTICS” and “ACCELERATE PHENO” and
“ACCELERATE PHENOTEST” and diamond shaped logos and marks are
trademarks or registered trademarks of Accelerate Diagnostics,
Inc.
For more information about the company, its products or
technology, visit axdx.com.
Forward-Looking Statements
Certain of the statements made in this press release are forward
looking, such as those, among others, about our projections as to
when certain key business milestones may be achieved, such as the
ongoing commercial launch, demand, and potential of our products or
technology, the growth of the market, our estimates as to the size
of our market opportunity and potential pricing, our competitive
position and estimates of time reduction to results, and our future
development plans and growth strategy. Actual results or
developments may differ materially from those projected or implied
in these forward-looking statements. Information about the risks
and uncertainties faced by Accelerate Diagnostics is
contained in the section captioned "Risk Factors" in the company's
most recent Annual Report on Form 10-K, filed with
the Securities and Exchange Commission on February
28, 2017, and in any other reports that we file with
the Securities and Exchange Commission from time to time.
The company's forward-looking statements could be affected by
general industry and market conditions. Except as required by
federal securities laws, the company undertakes no obligation to
update or revise these forward-looking statements to reflect new
events, uncertainties or other contingencies.
Investors May Contact:
Laura Pierson, Accelerate Diagnostics, +1 520 365-3100
investors@axdx.com
Reporters May Contact:
Andrew Chasteen, Accelerate Diagnostics, +1 520 365-3100
achasteen@axdx.com
Accelerate Diagnostics (NASDAQ:AXDX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Accelerate Diagnostics (NASDAQ:AXDX)
Historical Stock Chart
From Sep 2023 to Sep 2024